MedTrace Logo

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

NCT04809584 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2024-12-19

No results posted yet for this study

Summary

The purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI scan.

Conditions

Interventions

DRUG

F18-DCFPyL

Participant will be injected iv with 9 mCi ± 20% of 18F-DCFPyL

DRUG

Gadolinium

Contrast agent

PROCEDURE

Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan

Imaging test that combines PET (positron emission tomography) and MRI (magnetic resonance imaging)

Sponsors & Collaborators

Principal Investigators

  • Andrei H Iagaru · Stanford Universiy

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04809584 on ClinicalTrials.gov